Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for bluebird bio, Inc. (BLUE : NSDQ)
 
 • Company Description   
bluebird bio, Inc. is a clinical-stage biotechnology that is focused on developing gene therapies for severe genetic diseases and cancer. The company has developed a deep pipeline using lentiviral-based gene therapies, T-cell immunotherapy expertise, and gene editing capabilities to treat severe genetic diseases as well as cancer.?The pipeline for severe genetic diseases includes betibeglogene autotemcel (beti-cel) for the treatment of transfusion-dependent ?-thalassemia (TDT).

Number of Employees: 518

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.27 Daily Weekly Monthly
20 Day Moving Average: 2,479,301 shares
Shares Outstanding: 71.45 (millions)
Market Capitalization: $233.65 (millions)
Beta: 1.63
52 Week High: $23.87
52 Week Low: $3.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.45% -8.16%
12 Week -47.00% -41.74%
Year To Date -67.27% -59.03%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
60 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA
ph: 339-499-9300
fax: -
investor@bluebirdbio.com http://www.bluebirdbio.com
 
 • General Corporate Information   
Officers
Andrew Obenshain - ChiefExecutiveOfficer;President
Gina Consylman - Chief Financial Officer
Jessica Whitten - Vice President; Global Controller and Chief Accoun
Mark Vachon - Director
John O. Agwunobi - Director

Peer Information
bluebird bio, Inc. (CORR.)
bluebird bio, Inc. (RSPI)
bluebird bio, Inc. (CGXP)
bluebird bio, Inc. (BGEN)
bluebird bio, Inc. (GTBP)
bluebird bio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09609G100
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 71.45
Most Recent Split Date: (:1)
Beta: 1.63
Market Capitalization: $233.65 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.28 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.97 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 38.16% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.89
Price/Cash Flow: -
Price / Sales: 6.93
EPS Growth
vs. Year Ago Period: 45.93%
vs. Previous Quarter: 8.79%
Sales Growth
vs. Year Ago Period: -84.80%
vs. Previous Quarter: 21.11%
ROE
03/31/22 - -111.73
12/31/21 - -90.96
09/30/21 - -76.93
ROA
03/31/22 - -71.80
12/31/21 - -62.08
09/30/21 - -54.62
Current Ratio
03/31/22 - 1.78
12/31/21 - 2.20
09/30/21 - 3.12
Quick Ratio
03/31/22 - 1.78
12/31/21 - 2.20
09/30/21 - 3.12
Operating Margin
03/31/22 - -2,066.08
12/31/21 - -1,750.71
09/30/21 - -1,581.07
Net Margin
03/31/22 - -2,183.15
12/31/21 - -1,839.27
09/30/21 - -1,610.78
Pre-Tax Margin
03/31/22 - -1,670.90
12/31/21 - -15,357.18
09/30/21 - -1,502.56
Book Value
03/31/22 - 3.68
12/31/21 - 5.34
09/30/21 - 12.88
Inventory Turnover
03/31/22 - 13.06
12/31/21 - 4.80
09/30/21 - 3.10
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©